A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

Abstract

Nilotinib is a second-generation BCR-ABL kinase inhibitor with improved potency and selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to evaluate the efficacy, safety, and pharmacokinetics of nilotinib in Japanese patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous… (More)
DOI: 10.1007/s12185-009-0327-0

Topics

Cite this paper

@article{Tojo2009API, title={A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.}, author={Arinobu Tojo and Kensuke Usuki and Akio Urabe and Yasuhiro Maeda and Yukio Kobayashi and Itsuro Jinnai and Kazuma Ohyashiki and Miki Nishimura and T. Kawaguchi and H. Tanaka and Koichi Miyamura and Yasushi Miyazaki and Timothy P Hughes and Susan Branford and Shinichiro Okamoto and Jun Ishikawa and Masaya Okada and Noriko Usui and Hiromi Tanii and Taro Amagasaki and Hiroko Natori and Tomoki Naoe}, journal={International journal of hematology}, year={2009}, volume={89 5}, pages={679-88} }